Telesis Bio, Inc. (NASDAQ:TBIO) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET

Company Participants

Todd Nelson - Founder, Chief Executive Officer

Eric Esser - President, Chief Operating Officer

Jen Carroll - Vice President of Investor Relations

Conference Call Participants

Brandon Couillard - Jefferies

Paul Knight - KeyBanc

Steven Mah - TD Cohen

Operator

Good day, and thank you for standing by. Welcome to the Q2, 2023 Telesis Bio Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised, today's conference is being recorded.

I would now like to turn the conference over to your speaker today, Jen Carroll, Vice President of Investor Relations.

Jen Carroll

Thank you, and thanks for joining us for Telesis Bio's second quarter 2023 earnings call. With me on the call today are Telesis Bio Founder and Chief Executive Officer, Todd Nelson and our President and Chief Operating Officer, Eric Esser. Our second quarter 2023 financial results press release is now available on the Investors section of our website.

Before we begin, I would like to inform you that certain statements we make during the call will be forward-looking statements that involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the Safe Harbor Statement included in our earnings release and in our filings with the SEC.

This conference call contains time-sensitive information and is accurate only as of the live broadcast on August 10, 2023. Finally, any percent of changes we discuss will be on a year-over-year basis unless otherwise noted.

And with that, I will hand the call over to our CEO, Todd Nelson and we can get started.

Todd Nelson

Thanks, Jen. Welcome everyone and thanks for joining today's call. We're pleased with the progress the company is making in this challenging environment, and I want to highlight that this is the fourth consecutive quarter that we've successfully reduced or maintained our operating expenses while growing revenue on a year-over-year basis.

As you'll see in this quarter's results, we continue making progress with our strategic collaborations, which grew both our revenue and installed base, delivered new BioXp kits to the market, secured additional financing, and strengthened the Board of Directors through the addition of Paul Meister, former Chairman of ThermoFisher.